Gilead Sciences, Inc. (GILD) stock
GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 12/30104% above fair value
$168.98−1.28 (-0.75%)
Close on Nov 18, 2026Market cap $209.59BP/E –Yield 1.87%
Gilead Sciences pe ratio
The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.
Gilead Sciences's pe ratio was 17.7× on Jul 31, 2026, against 23.8× a year earlier. Over the last 5 years it ranged from 11.7× to 300.8×, with a median of 19.4×.
PE Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Jul 31, 2026 | 17.7× | −1.4 |
| 2025 | Dec 31, 2025 | 19.1× | −89.2 |
| 2024 | Oct 31, 2024 | 108.3× | +90.9 |
| 2023 | Dec 29, 2023 | 17.4× | −15.0 |
| 2022 | Dec 30, 2022 | 32.4× | +20.0 |
| 2021 | Dec 31, 2021 | 12.4× | −47.7 |
| 2020 | Dec 31, 2020 | 60.1× | +29.0 |
| 2019 | Dec 31, 2019 | 31.1× | −21.0 |
| 2018 | Dec 31, 2018 | 52.1× | +44.0 |
| 2017 | Dec 29, 2017 | 8.2× | +1.5 |
| 2016 | Dec 30, 2016 | 6.6× | −2.6 |
| 2015 | Dec 31, 2015 | 9.3× | −7.4 |
| 2014 | Dec 31, 2014 | 16.6× | −24.4 |
| 2013 | Dec 31, 2013 | 41.0× | +18.1 |
| 2012 | Dec 31, 2012 | 23.0× | +11.1 |
| 2011 | Dec 30, 2011 | 11.9× | +0.3 |
| 2010 | Dec 31, 2010 | 11.6× | −5.3 |
| 2009 | Dec 31, 2009 | 16.9× | – |
See a number that looks wrong?